Samsung will provide contract development organization services including cell line development, process development, current good manufacturing practice clinical manufacturing, and investigational new drug filing support.
PMC-403 is a novel agonistic antibody that binds to the human Tie2 receptor. PharmAbcine is developing the therapy to treat nonocular and ocular pathological vessel-related diseases. The company expects PMC-403 to enter a global ophthalmological clinical trial in 2022.
This is PharmAbcine's first significant undertaking of its angiogenesis assets outside of oncology applications.
Copyright © 2020 scienceboard.net